FDA finalizes guidances to accelerate development of Next Gen sequencing

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

FDA has finalized two guidances to drive the efficient development of a novel technology that scans a person’s DNA to diagnose genetic diseases, which are usually hereditary, and guide medical treatments. The guidances provide recommendations for designing, developing, and validating tests that use the technology, called next generation sequencing.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

Malcolm V. Brock, director of Clinical and Translational Research in Thoracic Surgery at Johns Hopkins Kimmel Comprehensive Cancer Center, grew up in Bermuda. His father insisted that his children branch outside the small island—the country has a population of just over 60,000 people—and challenge themselves abroad.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login